Fig. 7
From: Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
Therapeutic effect of δ-secretase inhibitor 11 on APP/PS1 mice. A Action of δ-secretase inhibitor 11 on AEP activity. B, C AEP activity, Aβ1–40 and Aβ1–42 in brain tissues of APP/PS1 mice treated with vehicle or δ-secretase inhibitor 11 (10 mg kg−1, p.o.) for 3 days. *P < 0.05, unpaired Student’s t-test; n = 5 mice per group. D The latency to the escape platform over the 5-day acquisition training. *P < 0.05, significant time and group effects, two-way ANOVA analysis. n = 10 mice per group. E, F The percentage of time and distance travelled in the target quadrant. *P < 0.05 between groups, one-way ANOVA, n = 10 mice per group. G 6E10 (arrowhead) in the hippocampus and cortex of APP/PS1 mice treated with δ-secretase inhibitor 11 or vehicle. Scale bar = 250 μm. H The average percentage of area occupied by 6E10-positive staining. *P < 0.05, Student’s t-test; n = 5 mice per group